A two-year-old biotech trying to get listed on the over-the-counter exchanges wouldn’t normally qualify for much notice. But OvaScience is...

We’ve got a short attention span this week, what with magazine deadlines, an overnight trip to Seattle to help interview participants a...

Last week’s column in Fortune Magazine by venture capitalist Lisa Suennen of the Psilos Group appropriately asked “ Hey, where are all the h...

Daily Dow watchers who were looking for a quick read on the private equity market might have felt a happy little jolt from the news that Ess...

What to make of the new €350 million fund raised by Index Ventures ? That the firm's LPs apparently like focus, except when they don...

It’s popular to suggest that the venture capital world is somewhat insulated by the turbulence on the public markets, but let’s get real. Th...

In most venture circles, talk around forming an international strategy generally leads to VCs staging fact-finding missions to China and Ind...

As we reported two weeks ago , Frazier Healthcare Ventures wrapped up $600 million for its sixth and largest health care fund to date. The n...

San Diego's life sciences start-up community took a bit of a hit recently. Enterprise Partners Venture Capital suspended its fundraisin...

News of Third Rock Ventures closing on its new $378 million fund got us thinking. It’s been a long, long time since a new potentially top-t...

Look around the newswires today and you’ll see Third Rock Ventures wrapped up $378 million for its debut venture capital fund. Great news, ...

It’s one of the oldest stories out there. Successful management team, a few years removed from running their own successful biopharmaceutica...